Ruth Pidsley

St. Vincent's Clinical School
Sydney, NSW 2052, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

DNA methylation estimates of immune cell abundance have prognostic potential in triple negative breast cancer.

DNA methylation estimates of immune cell abundance have prognostic potential in triple negative breast cancer.

Journal: Clinical epigenetics

Published: September 19, 2025

DNA methylation biomarkers for the diagnosis and treatment management of breast cancer: where are we now?

DNA methylation biomarkers for the diagnosis and treatment management of breast cancer: where are we now?

Journal: Epigenomics

Published: August 21, 2025

Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer.

Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer.

Journal: BJUI compass

Published: August 14, 2024

Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling.

Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling.

Journal: BMC genomics

Published: October 12, 2023

Detailed DNA methylation characterisation of phyllodes tumours identifies a signature of malignancy and distinguishes phyllodes from metaplastic breast carcinoma.

Detailed DNA methylation characterisation of phyllodes tumours identifies a signature of malignancy and distinguishes phyllodes from metaplastic breast carcinoma.

Journal: The Journal of pathology

Published: July 25, 2023

The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.

The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.

Journal: Nature structural & molecular biology

Published: December 13, 2022

Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality.

Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality.

Journal: Clinical and translational medicine

Published: March 24, 2022

A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.

A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.

Journal: Nature cancer

Published: September 28, 2021

Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer.

Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer.

Journal: Clinical epigenetics

Published: September 24, 2021

Advances in Prognostic Methylation Biomarkers for Prostate Cancer.

Advances in Prognostic Methylation Biomarkers for Prostate Cancer.

Journal: Cancers

Published: September 22, 2020

MethPanel: a parallel pipeline and interactive analysis tool for multiplex bisulphite PCR sequencing to assess DNA methylation biomarker panels for disease detection.

MethPanel: a parallel pipeline and interactive analysis tool for multiplex bisulphite PCR sequencing to assess DNA methylation biomarker panels for disease detection.

Journal: Bioinformatics (Oxford, England)

Published: August 26, 2020

Comprehensive evaluation of targeted multiplex bisulphite PCR sequencing for validation of DNA methylation biomarker panels.

Comprehensive evaluation of targeted multiplex bisulphite PCR sequencing for validation of DNA methylation biomarker panels.

Journal: Clinical epigenetics

Published: February 18, 2020

Showing 1-12 of 36

Last Updated: 09/26/2026